Gujarat Themis Biosyn Ltd (GUJTHEM)
₹363.20
Mkt cap
₹4,727 Cr
P/E ratio
97.10
P/B
13.76
Div yield
0.18%
ROE
17.40%
ROCE
18.10%
EPS (TTM)
₹3.74
Book value
₹26
52W range
225–479
Sector
Healthcare
Price history
Previous close
Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process [1]
NSE GUJTHEMBSE 506879
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−24.18% from high₹363
₹225+61.39% from low₹479
Current
₹363.20
Prev close
₹375.80
Day
−3.35%
Price performance
1D
−4.10%
1W
+11.23%
1M
−11.34%
3M
+2.53%
6M
−4.06%
1Y
−20.33%
YTD
−16.54%
Financials
Revenue, profit & margin
P/E ratio
97.1×
GUJTHEM is 182% above the sector median of 34.4×
GUJTHEM97.1×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50 | 40 | 39 | 42 | 39 | 35 | 40 | 38 | 36 | 42 | 43 | 44 | 44 | |
| Expenses | 26 | 23 | 21 | 21 | 20 | 19 | 21 | 22 | 22 | 21 | 22 | 25 | 23 | |
| Operating Profit | 24 | 17 | 18 | 21 | 19 | 15 | 19 | 16 | 14 | 21 | 21 | 19 | 21 | |
| OPM % | 47% | 42% | 46% | 50% | 48% | 44% | 48% | 42% | 39% | 49% | 49% | 44% | 48% | |
| Other Income | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 4 | 4 | |
| Profit before tax | 24 | 17 | 18 | 21 | 18 | 14 | 17 | 16 | 12 | 19 | 17 | 14 | 15 | |
| Tax % | 26% | 26% | 26% | 24% | 26% | 26% | 25% | 25% | 25% | 24% | 26% | 24% | 27% | |
| Net Profit | 18 | 13 | 13 | 16 | 13 | 11 | 13 | 12 | 9 | 14 | 12 | 11 | 11 | |
| EPS in Rs | 1.63 | 1.15 | 1.19 | 1.46 | 1.21 | 0.97 | 1.19 | 1.10 | 0.83 | 1.31 | 1.14 | 1.00 | 1.02 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
4 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.64% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 7 Aug '26 |
| Earnings day | −1.64% |
| +1 day | +1.56% |
| +5 days | −3.63% |
| +15 days | +13.58% |
| +30 days | +14.31% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202659.33%Promoter
Promoters59.33%11.54
FIIs3.80%2.04
DIIs12.65%11.48
Public24.21%1.97
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Guj. Themis Bio. | ₹363.20 | 97.11 | 4,727 | 0.18% | 11 | +22.19% | 44 | +22.08% | 18.10% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts32
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 Oct - Please refer to our Intimation of Investor & Analyst Meet scheduled on 5th November, 2026Board Meeting Intimation for Consideration And Approval Of Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30.09.2026 27 Oct - Board meets on 4 Nov 2026 to approve Q2 and half-year FY27 results; trading window closed1 Oct 2026.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 Oct - Kindly refer to the RTA compliance Certificate for the quarter ended 30.09.2026.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 1 Oct - 45th AGM voting results घोषित on 30 Sept 2026; all resolutions passed, including FY26 accounts and director reappointment.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 1 Oct